Two performances of Johnson and Johnson, Alex Gorski Sherilyn McCoy, now apparently are lead candidates to succeed CEO William Weldon, which is expected to retire in the next year or so, as the WSJ reports.
Weldon, who also serves as President, is 62, but there is no mandatory retirement age.
J & J appointed two executions "expanded Office of the President" and gave them new functions such as vice presidents of the Executive Committee.
Gorski, who currently leads the business of medical devices and diagnostics, unit now also oversee the global supply chain, Government Affairs and policy J & J venture arm.
McCoy, now head of pharma J & J, enterprise will be also responsible for consumer is reminder unit society, the Head Office of science and technology and Corporate Affairs.
"These appointments will ensure we are well positioned for sustainable growth in the future," Weldon said in a statement. "Change is an appropriate step to deepen our long-term succession plans and ensure the talented chefs experienced at all levels of the organization."
Other pharmaceutical companies make changes at the top right now. Jeffrey Kindler recently took his retirement as CEO of Pfizer, distribute the reins to Ian Read. There are a few weeks ago, Merck named Kenneth Frazier, the incoming President and Chief Executive.
Photo by Harry Willis via Flickr
No comments:
Post a Comment